Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetazolamide vs Diazepam in CSWS/LKS
NCT02904265Phase 3Terminated
- Sponsor
- Mayo Clinic
- Start
- Sep 2016
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of acetazolamide in Landau-Kleffner syndrome (LKS) and Electrical status epilepticus in sleep (ESES) (2 arms), sponsored by Mayo Clinic. Primary endpoint: Short-term Tolerability of Acetazolamide vs Diazepam. Started Sep 2016; status: terminated.
02
Drugs
acetazolamide
03
Conditions
Landau-Kleffner syndrome (LKS)Electrical status epilepticus in sleep (ESES)
Beyond the preview
Go deeper on NCT02904265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02904265.